公开(公告)号：US08883822B2

公开(公告)日：2014-11-11

申请号：US13887177

申请日：2013-05-03

申请人： Samumed, LLC ,  Samumed, LLC

发明人： John Hood ,  Sunil Kumar KC ,  David Mark Wallace

IPC分类号： C07D401/14 ,  A61K31/437

CPC分类号： A61K31/444 ,  A61K9/0019 ,  A61K9/0078 ,  A61K9/10 ,  A61K9/14 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  C07D401/14 ,  C07D471/04 ,  C07D519/00

摘要： Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.

摘要翻译： 本文提供了根据式（I）或（II）的化合物及其药学上可接受的盐，以及包含其的组合物，用于各种方法，包括治疗癌症，异常细胞增殖，血管生成，阿尔茨海默氏病，肺病，骨关节炎， 特发性肺纤维化和神经病症/疾病/疾病。

公开(公告)号：US10882860B2

公开(公告)日：2021-01-05

申请号：US16710099

申请日：2019-12-11

申请人： Samumed, LLC

发明人： John Hood ,  David Mark Wallace ,  Sunil Kumar KC ,  Yusuf Yazici ,  Christopher Swearingen ,  Luis A Dellamary

IPC分类号： C07D513/02 ,  C07D515/02 ,  A61K31/44 ,  C07D471/04 ,  A61K31/444 ,  A61P19/02 ,  A61P29/00 ,  A61K31/496 ,  A61K31/5377 ,  A61K9/00 ,  A61K31/4545

摘要： Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.

公开(公告)号：US10806726B2

公开(公告)日：2020-10-20

申请号：US15790544

申请日：2017-10-23

申请人： Samumed, LLC

发明人： Vishal Deshmukh ,  Eric Anthony Murphy ,  John Hood

IPC分类号： A61K31/444 ,  A61P19/04 ,  A61P17/00 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/501 ,  A61P17/06 ,  A61K31/4545 ,  A61K31/5355

摘要： This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

公开(公告)号：US10544139B2

公开(公告)日：2020-01-28

申请号：US15773951

申请日：2016-11-07

申请人： Samumed, LLC

发明人： John Hood ,  David Mark Wallace ,  Sunil Kumar KC ,  Yusuf Yazici ,  Christopher Swearingen ,  Luis A Dellamary

IPC分类号： C07D513/02 ,  C07D515/02 ,  A61K31/44 ,  C07D471/04 ,  A61K31/444 ,  A61P19/02 ,  A61P29/00 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K9/00

摘要： Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.

公开(公告)号：US10463651B2

公开(公告)日：2019-11-05

申请号：US15749586

申请日：2016-08-03

申请人： Samumed, LLC

发明人： Sunil Kumar KC ,  David Mark Wallace ,  Jianguo Cao ,  Chandramouli Chiruta ,  John Hood

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P19/02 ,  A61P11/00 ,  A61P19/10 ,  A61P35/00

摘要： Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

公开(公告)号：US10407425B2

公开(公告)日：2019-09-10

申请号：US15968555

申请日：2018-05-01

申请人： Samumed, LLC

发明人： John Hood ,  David Mark Wallace ,  Sunil Kumar KC

IPC分类号： A61K31/437 ,  C07D401/14 ,  C07D471/04

摘要： Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

公开(公告)号：US10314832B2

公开(公告)日：2019-06-11

申请号：US15855463

申请日：2017-12-27

申请人： Samumed, LLC

发明人： Sunil Kumar Kc ,  David Mark Wallace ,  John Hood ,  Charlene F. Barroga

IPC分类号： A61K9/00 ,  A61K31/12 ,  A61K31/357 ,  A61K31/381 ,  C07D213/50 ,  C07D319/16 ,  C07D319/18 ,  C07D405/06 ,  C07D405/10 ,  C07D407/10 ,  C07D409/06 ,  C07D409/10 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/4436 ,  C07C49/784

摘要： The present application discloses a compound which is which activates Wnt/β-catenin signaling and thus treats or prevents diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

公开(公告)号：US10285983B2

公开(公告)日：2019-05-14

申请号：US15749727

申请日：2016-08-03

申请人： Samumed, LLC

发明人： Sunil Kumar KC ,  David Mark Wallace ,  Jianguo Cao ,  Chandramouli Chiruta ,  John Hood

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P19/02 ,  A61P11/00 ,  A61P19/08 ,  A61P35/00 ,  C07D519/00

摘要： 7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

公开(公告)号：US20190119303A1

公开(公告)日：2019-04-25

申请号：US16162155

申请日：2018-10-16

申请人： Samumed, LLC

发明人： Sunil Kumar KC ,  David Mark Wallace ,  Jianguo Cao ,  Chandramouli Chiruta ,  John Hood

IPC分类号： C07D519/00

CPC分类号： C07D519/00

摘要： Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

公开(公告)号：US10226453B2

公开(公告)日：2019-03-12

申请号：US15749739

申请日：2016-08-03

申请人： Samumed, LLC

发明人： Sunil Kumar KC ,  David Mark Wallace ,  Jianguo Cao ,  Chandramouli Chiruta ,  John Hood

IPC分类号： C07D401/14 ,  C07D401/10 ,  A61K31/437 ,  A61K31/4353 ,  A61P19/00 ,  A61P35/00 ,  A61K31/4162 ,  C07D471/04 ,  C07D519/00

摘要： 4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.